公开(公告)号：US09301969B2

公开(公告)日：2016-04-05

申请号：US13822641

申请日：2011-09-09

申请人： Jae-Kyu Roh ,  Sang Kun Lee ,  Man Ho Kim ,  Kon Chu ,  Keun-Hwa Jung ,  Soon-Tae Lee

发明人： Jae-Kyu Roh ,  Sang Kun Lee ,  Man Ho Kim ,  Kon Chu ,  Keun-Hwa Jung ,  Soon-Tae Lee

IPC分类号： A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  C12Q1/68

CPC分类号： A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease.

摘要翻译： 本发明涉及通过靶向特异性miRNA来预防或治疗神经变性疾病的药物组合物。 此外，本发明涉及用于诊断神经变性疾病的试剂盒。 在阿尔茨海默病和人类大脑样本的两种动物模型中高度表达的本发明中发现的miR-206靶是选择没有神经错误的实质性治疗靶。 作为miR-206的抑制剂的本发明的反义寡核苷酸表明通过靶向miRNA来治疗神经退行性疾病是成功的结果。 本发明的反义寡核苷酸抑制miR-206的功能，大大增加BDNF和IGF-1的水平，并增加突触的再生，从而治疗神经变性疾病，特别是阿尔茨海默氏病。

公开(公告)号：US20130184331A1

公开(公告)日：2013-07-18

申请号：US13822641

申请日：2011-09-09

申请人： Jae-Kyu Roh ,  Sang Kun Lee ,  Man Ho Kim ,  Kon Chu ,  Keun-Hwa Jung ,  Soon-Tae Lee

发明人： Jae-Kyu Roh ,  Sang Kun Lee ,  Man Ho Kim ,  Kon Chu ,  Keun-Hwa Jung ,  Soon-Tae Lee

IPC分类号： A61K31/7088 ,  C12Q1/68

CPC分类号： A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease.

摘要翻译： 本发明涉及通过靶向特异性miRNA来预防或治疗神经变性疾病的药物组合物。 此外，本发明涉及用于诊断神经变性疾病的试剂盒。 在阿尔茨海默病和人类大脑样本的两种动物模型中高度表达的本发明中发现的miR-206靶是选择没有神经错误的实质性治疗靶。 作为miR-206的抑制剂的本发明的反义寡核苷酸表明通过靶向miRNA来治疗神经退行性疾病是成功的结果。 本发明的反义寡核苷酸抑制miR-206的功能，大大增加BDNF和IGF-1的水平，并增加突触的再生，从而治疗神经变性疾病，特别是阿尔茨海默氏病。